Shanghai Henlius Biotech, Inc.
2696
Classifica tra le azioni
#4239
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Prezzo delle azioni
$6.90
Capitalizzazione di mercato
$3.76B
Variazione (1 giorno)
3.15%
Variazione (1 anno)
-26.92%
Paese
CN
Scambia Shanghai Henlius Biotech, Inc. (2696)
Categoria
Healthcare
Numero di azioni in circolazione per Shanghai Henlius Biotech, Inc. (2696)
Numero di azioni in circolazione al June 2026: 544.86M
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Shanghai Henlius Biotech, Inc., il numero attuale di azioni in circolazione è 544.86M. Alla fine del December 2023, la società aveva 546.02M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Shanghai Henlius Biotech, Inc. (2696) dal 2017 al 2026
Azioni in circolazione alla fine di ogni anno
| Anno | Azioni in circolazione | Cambia |
|---|---|---|
| 2026 (TTM) | 544.86M | 0.25% |
| 2024 | 543.50M | -0.46% |
| 2023 | 546.02M | 0.74% |
| 2022 | 542.02M | 0.80% |
| 2021 | 537.73M | 1.75% |
| 2020 | 528.48M | 6.30% |
| 2019 | 497.16M | -4.53% |
| 2018 | 520.74M | -3.41% |
| 2017 | 539.13M | 0.00% |
Azioni in circolazione per aziende simili o concorrenti
| Azienda | Azioni in circolazione | Differenza | Il paese |
|---|---|---|---|
| 253.90M | -53.40% |
US
|
|
| 396.00M | -27.32% |
US
|
|
| 478.91M | -12.10% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -88.59% |
NL
|
